Pacira BioSciences (PCRX) Amortization of Deferred Charges (2023 - 2026)

Pacira BioSciences' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $521000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 39.91% year-over-year to $521000.0; the TTM figure through Mar 2026 stood at $2.5 million (down 26.17% YoY), while the FY2025 annual figure was $2.8 million, down 11.86% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $521000.0, roughly flat from $520000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $1.4 million in Q4 2023, with the low at $520000.0 in Q4 2025.
• The 4-year median for Amortization of Deferred Charges is $763000.0 (2024), against an average of $796384.6.
• Peak annual rise in Amortization of Deferred Charges reached 27.31% in 2025, while the deepest fall reached 44.56% in 2025.
• Pacira BioSciences' Amortization of Deferred Charges stood at $1.4 million in 2023, then slumped by 34.73% to $938000.0 in 2024, then tumbled by 44.56% to $520000.0 in 2025, then grew by 0.19% to $521000.0 in 2026.
• Business Quant data shows PCRX's Amortization of Deferred Charges at $521000.0 in Q1 2026, $520000.0 in Q4 2025, and $626000.0 in Q3 2025.